Vitamin D deficiency is associated with the development of subclinical coronary artery disease in african americans with hiv infection: A preliminary study

Journal of Investigative Medicine

Volumn 60, Issue 5, 2012, Pages 801-807

  Lai, Hong ^a   Detrick, Barbara ^a   Fishman, Elliot K ^a   Gerstenblith, Gary ^a   Brinker, Jeffrey A ^a   Hollis, Bruce W ^b   Bartlett, John ^b   Cofrancesco, Joseph ^a   Tong, Wenjing ^a   Tai, Hong ^a   Chen, Shaoguang ^a   Bhatia, Sandeepan ^a   Lai, Shenghan ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

African Americans; HIV infection; Subclinical coronary artery disease; Vitamin D deficiency

Indexed keywords

ANTIRETROVIRUS AGENT; COCAINE;

ADULT; AFRICAN AMERICAN; ATHEROSCLEROTIC PLAQUE; CALCIFICATION; CARDIAC IMAGING; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PREVALENCE; VIRUS LOAD; VITAMIN D DEFICIENCY;

HUMAN IMMUNODEFICIENCY VIRUS;

ADULT; AFRICAN AMERICANS; CORONARY ARTERY DISEASE; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; VITAMIN D DEFICIENCY;

EID: 84860806123     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0b013e318250bf99     Document Type: Conference Paper

References (34)

1. Eugenin EA, Morgello S, Klotman ME, et al. Human immunodeficiency virus (HIV) infects human arterial smooth muscle cells in vivo and in vitro: Implications for the pathogenesis of HIV-mediated vascular disease. Am J Pathol. 2008;172(4):1100-1111. (Pubitemid 351520006)
2. Barbaro G. Heart and HAART: Two sides of the coin for HIV-associated cardiology issues. World J Cardiol. 2010;2(3):53-57.
3. Bozzette SA, Ake CF, Tam HK, et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med. 2003;348:702-710. (Pubitemid 36237039)
4. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2004.
5. The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723-1735.
6. Lai S, Lai H, Vlahov D, et al. HIV-1 infection, cocaine, and coronary calcification. Arch Intern Med. 2005;165:690-695. (Pubitemid 40393154)
7. Lai S, Fishman EK, Lai H, et al. Long-term cocaine use and antiretroviral therapy are associated with silent coronary artery disease in cardiovascularly asymptomatic African Americans with HIV who have no cardiovascular symptoms. Clin Infect Dis. 2008;46:600-610. (Pubitemid 351263503)
8. Lai S, Bartlett J, Lai H, et al. Long-term combination antiretroviral therapy is associated with the risk of coronary plaques in African Americans with HIV Infection. AIDS Patient Care STDs. 2009;23(10):815-824.
9. Ferdinand KC. Coronary heart disease and lipid-modifying treatment in African American patients. Am Heart J. 2004:147:774-782. (Pubitemid 38880981)
10. Ersfeld DL, Rao DS, Body JJ, et al. Analytical and clinical validation of the 25(OH) vitamin D assay for the Liaison automated analyzer. Clin Biochem. 2004;37:867-874. (Pubitemid 39209026)
11. Miller JM, Rochitte CE, Dewey M, et al. Diagnostic performance of coronary angiography by 64-row CT. N Engl J Med. 2008;359(22):2324-2336.
12. Wilson PWF, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847. (Pubitemid 28213628)
13. Roger VL, Go AS, Lloyd-Jones DM, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statisticsV2011 update: A report from the American Heart Association. Circulation. 2011;123(4):e18-e209. E-pub 2010.
14. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657-671.
15. Anand DV, Lim E, Raval U, et al. Prevalence of silent myocardial ischemia in asymptomatic individuals with subclinical atherosclerosis detected by electron beam tomography. J Nucl Cardiol. 2004;11(4):450-457. (Pubitemid 39107082)
16. Wilson PW, Castelli WP, Kannel WB. Coronary risk prediction in adults (the Framingham Heart Study). Am J Cardiol. 1987;59(14):91G-94G. (Pubitemid 17085552)
17. May HT, Horne BD, Bair TL, et al. Intermountain Heart Collaborative (IHC) Study Group. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol. 2010;106(7):963-968. E-pub Aug 11, 2010.
18. Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117:503-511.
19. Lai H, Fishman EK, Gerstenblith G, et al. Vitamin D deficiency is associated with significant coronary stenoses in asymptomatic African American chronic cocaine users. Int J Cardiol. 2011. [E-pub ahead of print].
20. Wortsman J, Matsuoka LY, Chen TC, et al. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr. 2000;72:690-693. (Pubitemid 30667088)
21. Martins D, Wolf M, Pan D, et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: Data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2007;167:1159-1165. (Pubitemid 46919818)
22. Krause R, Buhring M, Hopfenmuller W, et al. Ultraviolet B and blood pressure. Lancet. 1998;352:709-710. (Pubitemid 28398716)
23. Zittermann A. Vitamin D and disease prevention with special reference to cardiovascular disease. Prog Biophys Mol Biol. 2006;92:39-48. (Pubitemid 43831966)
24. Dobnig H, Pilz S, Scharnagl H, et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med. 2008;168(12):1340-1349. (Pubitemid 351930842)
25. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin DYmediated human antimicrobial response. Science. 2006;311(5768):1770- 1773.
26. Overton ET, Yin MT. The rapidly evolving research on vitamin D among HIV-infected populations. Curr Infect Dis Rep. 2011;13:83-93.
27. Carthy EP, Yamashita W, Hsu A, et al. 1,25-Dihydroxyvitamin D3 and rat vascular smooth muscle cell growth. Hypertension. 1989;13(6 Pt 2):954-959. (Pubitemid 19157996)
28. Mitsuhashi T, Morris RC Jr, Ives HE. 1,25-Dihydroxyvitamin D3 modulates growth of vascular smooth muscle cells. J Clin Invest. 1991;87(6):1889-1895.
29. Wu-Wong JR, Nakane M, Ma J, et al. Effects of vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells. Atherosclerosis. 2006;186(1):20-28.
30. Chen S, Law CS, Gardner DG. Vitamin DYdependent suppression of endothelin-induced vascular smooth muscle cell proliferation through inhibition of CDK2 activity. J Steroid Biochem Mol Biol. 2010;118(3):135-141.
31. Chen S, Law CS, Grigsby CL, et al. A role for the cell cycle phosphatase Cdc25a in vitamin DYdependent inhibition of adult rat vascular smooth muscle cell proliferation. J Steroid Biochem Mol Biol. 2010;122(5):326-332.
32. Harris RA, Pedersen-White J, Guo DH, et al. Vitamin d(3) supplementation for 16 weeks improves flow-mediated dilation in overweight African American adults. Am J Hypertens. 2011;24(5):557-562.
33. Dong Y, Stallmann-Jorgensen IS, Pollock NK, et al. A 16-week randomized clinical trial of 2000 international units daily vitamin D3 supplementation in black youth: 25-hydroxyvitamin D, adiposity, and arterial stiffness. J Clin Endocrinol Metab. 2010;95(10):4584-4591.
34. Yoon HC, Goldin JG, Greaser LE 3rd, et al. Interscan variation in coronary artery calcium quantification in a large asymptomatic patient population. AJR Am J Roentgenol. 2000;174(3):803-809. (Pubitemid 30126267)